ASCO-2021 Express: Glioblastoma, temozolomide adds 6 additional treatment cycles, which is not beneficial to overall survival

The GEINO 1401 trial (NCT02209948) of the Grupo Español de Investigación en Neurooncología team from Spain will randomly divide patients diagnosed with glioblastoma and treated with chemotherapy and adjuvant temozolomide (TMZ) into 12 who will receive extended use of TMZ Cycle or control treatment.

They found no difference in progression-free survival (PFS) and overall survival (OS) at 6 months.

They randomized 159 patients who were diagnosed with glioblastoma and received standard treatment (ratio 1:1) and asked them to stop treatment or continue to use TMZ for up to 12 cycles.

They found that during a median follow-up of 20 months, 82.

The median OS of the control group was 22.

In addition, they also found that the incidence of methylated MGMT is higher in LTSP.

The core conclusion of this RCT is to find that adding 6 cycles of TMZ after the first 6 cycles of adjuvant therapy has no additional benefit to OS.

Original source:

https://ascopubs.

Marta Domenech, Carles Fabregat-Franco, et al.

DOI: 10.